ClinicalTrials.gg
RecruitingNCT07383025Updated Feb 3, 2026

Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan

An observational study in Obstructive Hypertrophic Cardiomyopathy (oHCM), sponsored by Bristol-Myers Squibb. Recruiting at 1 site in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-03.

Sponsored by Bristol-Myers Squibb · Observational

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb — 10 open to participants now, 15 under way, 2 of them phase 3. Cardiomyopathy, Hypertrophic · Bristol-Myers Squibb.

Planned enrollment
8th of 15
200 · median 200
Started
2025
with 1 other
Observational
15 of 32
9 open now
Primary completion
2029-11
later than 14 of 14 live
Registered
28th of 32
by date

Among the 32 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb, this one is the 8th largest by planned enrollment of the 15 observational ones that give a count, is one of 2 that started in 2025, is one of 15 observational ones, reaches primary completion later than 14 of the 14 other live ones, and was the 28th registered.

Cardiomyopathy, Hypertrophic

365 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 118 are open to participants now.

Browse Cardiomyopathy, Hypertrophic studies →

Open to participants now

10 of the 32 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Who these studies take

Of the 82 Cardiomyopathy, Hypertrophic studies recruiting now, 56 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to assess the real-world effectiveness and safety of mavacamten in patients with obstructive hypertrophic cardiomyopathy (HCM) receiving mavacamten in Japan

03

Conditions studied

  • Obstructive Hypertrophic Cardiomyopathy (oHCM)

Keywords

  • Obstructive hypertrophic cardiomyopathy (oHCM)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

The study population will consist of adults diagnosed with obstructive hypertrophic cardiomyopathy (oHCM) who initiate mavacamten treatment at medical institutions in Japan

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All obstructive hypertrophic cardiomyopathy (oHCM) patients who initiate treatment with Mavacamten of the approved indications at medical institutions in Japan during enrollment period will be enrolled in this regulatory post-marketing surveillance (PMS) study

Exclusion criteria

Exclusion Criteria:

  • Participants receiving Mavacamten for an off-label indication will be excluded from this PMS study
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cohort 1

    Participants with obstructive hypertrophic cardiomyopathy receiving mavacamten treatment

    Drug: Mavacamten

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events (AEs) and/or serious AEs (SAEs)

    Time frame: Up to 52 weeks

  2. Actions taken after adverse events (AEs) and/or serious AEs (SAEs)

    Time frame: Up to 52 weeks

  3. Outcome of adverse events (AEs) and/or serious AEs (SAEs)

    Time frame: Up to 52 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Nov 2029, 54 months after the start.

Of 82 observational studies under Cardiomyopathy, Hypertrophic, half reached primary completion within 85 months of starting (the median), counting those still running; a quarter within 43. This study's planned 54 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2026
First posted
Feb 3, 2026
StartActual
May 21, 2025
Primary completionEst.
Nov 30, 2029
CompletionEst.
Nov 30, 2029
Last update
Feb 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07383025
Responsible party
Sponsor
First posted
Feb 3, 2026
Start date
May 21, 2025
Primary completion
Nov 30, 2029 (estimated)
Completion
Nov 30, 2029 (estimated)
Last update
Feb 3, 2026

Study contacts

BMS Study Connect Contact Center www.BMSStudyConnect.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristol Myers Squibb
study director · Bristol-Myers Squibb

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion